OSA vs. INVO, UTRS, GMVDF, OSAP, AEMD, NMRD, TNON, DYNT, QNRX, and TMDIF
Should you be buying ProSomnus stock or one of its competitors? The main competitors of ProSomnus include INVO Bioscience (INVO), Minerva Surgical (UTRS), G Medical Innovations (GMVDF), ProSomnus (OSAP), Aethlon Medical (AEMD), Nemaura Medical (NMRD), Tenon Medical (TNON), Dynatronics (DYNT), Quoin Pharmaceuticals (QNRX), and Titan Medical (TMDIF). These companies are all part of the "surgical & medical instruments" industry.
ProSomnus (NASDAQ:OSA) and INVO Bioscience (NASDAQ:INVO) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their community ranking, media sentiment, earnings, analyst recommendations, institutional ownership, dividends, risk, valuation and profitability.
70.0% of ProSomnus shares are held by institutional investors. Comparatively, 12.0% of INVO Bioscience shares are held by institutional investors. 7.7% of ProSomnus shares are held by insiders. Comparatively, 3.5% of INVO Bioscience shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
ProSomnus has a net margin of -87.14% compared to INVO Bioscience's net margin of -459.42%.
In the previous week, ProSomnus had 1 more articles in the media than INVO Bioscience. MarketBeat recorded 2 mentions for ProSomnus and 1 mentions for INVO Bioscience. ProSomnus' average media sentiment score of 0.00 equaled INVO Bioscience'saverage media sentiment score.
INVO Bioscience has lower revenue, but higher earnings than ProSomnus. ProSomnus is trading at a lower price-to-earnings ratio than INVO Bioscience, indicating that it is currently the more affordable of the two stocks.
ProSomnus has a beta of 0.21, indicating that its stock price is 79% less volatile than the S&P 500. Comparatively, INVO Bioscience has a beta of 1.45, indicating that its stock price is 45% more volatile than the S&P 500.
INVO Bioscience received 3 more outperform votes than ProSomnus when rated by MarketBeat users. However, 80.00% of users gave ProSomnus an outperform vote while only 46.67% of users gave INVO Bioscience an outperform vote.
ProSomnus presently has a consensus price target of $2.33, indicating a potential upside of 1,566.67%. Given ProSomnus' higher probable upside, equities research analysts clearly believe ProSomnus is more favorable than INVO Bioscience.
Summary
ProSomnus beats INVO Bioscience on 9 of the 15 factors compared between the two stocks.
Get ProSomnus News Delivered to You Automatically
Sign up to receive the latest news and ratings for OSA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding OSA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
ProSomnus Competitors List
Related Companies and Tools
